Search Results

Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma (OPTec/OPTal) MOA: Teclistamab targets the CD3 receptor complex on T cells and BCMA on B-lineage cells. Talquetamab targets the D3 receptor complex in T cells and GPRC5D expressing cells. Key Eligibility Criteria: Must have documented diagnosis of MM according to the IMWG diagnostic criteria Must have…

A medical professional points to a chest X-ray displayed on a tablet during a consultation. Receiving a lung cancer diagnosis can be overwhelming, and you may have questions about your options and what comes next. Fortunately, there is hope through the many recent advances made in lung cancer treatment. Immunotherapy Treatments Help Immune System Target…

Phase 2 Single Arm Trial with a Safety Lead-in of Tucatinib in Combination with Doxil for the Treatment of HER2+ Metastatic Breast Cancer (BRE 381) MOA: Tucatinib is an oral tyrosine kinase inhibitor selective for HER2 Doxil is an anthracycline topoisomerase II inhibitor Key Eligibility Criteria: Women, men with HER2+ metastatic breast cancer (IHC3+ or…

Understanding Mammogram Recalls Tech capturing image during a routine mammogram It is not unusual to get recalled after an initial screening mammogram. Additional imaging is often requested so that a clearer view of a particular area of breast tissue can be captured. Fewer than one in 10 women who return for additional testing are found…

A Phase Ib/III, Open-label, Randomised Study of Capivasertib plus CDK4/6 Inhibitors and Fulvestrant versus CDK4/6 Inhibitors and Fulvestrant in Hormone Receptor-Positive and Human Epidermal Growth Factor Receptor 2-Negative Locally Advanced, Unresectable or Metastatic Breast Cancer (CAPItello-292) MOA: Capivasertib is an oral pan-AKT inhibitor Key Eligibility Criteria: Men and women with adv/metastatic HR+/HER2- breast cancer Pre-/perimenopausal…

A Phase III, Randomized, Open-Label, Multi-Center, Global Study of Volrustomig as Sequential Therapy Versus Observation in Participants with Unresected Locally Advanced-Head and Neck Squamous Cell Carcinoma (LA-HNSCC) Who Have Not Progressed Following Definitive Concurrent Chemoradiotherapy  (eVOLVE-HNSCC) MOA: Checkpoint inhibitor Volrustomig (MEDI5752): Monovalent, bispecific, anti-PD-1 / anti-CTLA-4 humanized IgG1 mAb Key Eligibility Criteria: Locally advanced squamous…